To reach the next value inflection
LicenseRx asset brief
Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases
Probability of Success
24% · grade B · Medium data confidence
Model PoS 24% (grade B, medium data confidence). Strongest signals: IP position, Data maturity. Biggest drag: Translational evidence.
Data maturity (22%)
59
Preclinical; in vivo data.
IP position (16%)
88
Issued/granted patent on record.
Modality feasibility (14%)
65
Modality unclear from public data -- assumed average development risk.
Indication pull (14%)
78
Immunology, Inflammation -- active buyer appetite.
Competitive whitespace (12%)
68
Average room to differentiate vs. incumbents.
Translational evidence (12%)
54
Public evidence mentions: in vivo.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →